ArriVent BioPharma, Inc. Financial Disclosures & SEC Filings
This page provides a comprehensive overview of ArriVent BioPharma, Inc.'s financial disclosures and SEC filings, including annual reports (10-K), quarterly reports (10-Q), and earnings releases (8-K). It details key corporate events, earnings summaries, and pipeline progress from 2023 to 2026, highlighting clinical advancements in NSCLC and the company's financial position.
Price to earnings forward of ArriVent BioPharma, Inc. – NASDAQ:AVBP
The article focuses on the price-to-earnings forward metric for ArriVent BioPharma, Inc. (NASDAQ: AVBP). It provides navigation and structural elements typical for a financial data platform, indicating where users can find financials, news, community, and technical analysis for the company. The content itself seems to be a placeholder or a section title for detailed financial data.
Price to book forward of ArriVent BioPharma, Inc. – BOATS:AVBP
This page provides financial information for ArriVent BioPharma, Inc. (AVBP) on the Blue Ocean Alternative Trade System (BOATS). It specifically highlights the "Price to book forward" metric for the company. The content also details various features and services offered by TradingView, including market data, charting tools, and community resources.
Number of shareholders of ArriVent BioPharma, Inc. – BOATS:AVBP
This article focuses on the number of shareholders for ArriVent BioPharma, Inc. (AVBP), referencing data from the Blue Ocean Alternative Trade System (BOATS) via TradingView. The content primarily displays navigation and boilerplate information typical of a financial data platform, with the actual shareholder data section remaining blank.
Price to book forward of ArriVent BioPharma, Inc. – NASDAQ:AVBP
This page from TradingView displays the "Price to book forward" financial metric for ArriVent BioPharma, Inc. (NASDAQ:AVBP). It indicates that the market was closed at the time of access with no trades occurring. The content is primarily a data placeholder within a financial platform's interface.
Price to earnings forward of ArriVent BioPharma, Inc. – BOATS:AVBP
This article provides financial information for ArriVent BioPharma, Inc. (AVBP) with a focus on its price-to-earnings forward metric. The content highlights the company's financials, news, and market data available through the TradingView platform. It appears to be a financial data page rather than a traditional article.
AVBP Forecast — Price Target — Prediction for 2027
The article provides a forecast for ArriVent BioPharma, Inc. (AVBP) stock, including a 1-year price target of $43.92 based on 12 analysts. It details current stock performance, historical highs and lows, volatility, market capitalization, and upcoming earnings information. The analysis also includes current analyst ratings, largely indicating a "strong buy" signal.
ArriVent BioPharma, Inc. Actuals & Estimates (NASDAQ:AVBP)
This article provides an overview of ArriVent BioPharma, Inc. (NASDAQ:AVBP), presenting its current stock price, historical performance, and analyst forecasts. It includes key financial metrics like market capitalization, earnings per share, and revenue, alongside details on volatility and upcoming earnings reports. The content also addresses frequently asked questions about investing in AVBP stock.
ArriVent BioPharma (AVBP) director receives 13,562 stock options at $31.74
ArriVent BioPharma director Chris Nolet was granted 13,562 non-qualified stock options with an exercise price of $31.74 per share. These options are set to expire on June 17, 2036, and the underlying shares will vest on June 18, 2027, contingent on his continued service. The transaction is categorized as a grant/award and does not involve an open-market purchase or sale.
ArriVent BioPharma (AVBP) director receives grant of 13,562 stock options at $31.74
ArriVent BioPharma, Inc. (AVBP) director John Hohneker was granted 13,562 non-qualified stock options with an exercise price of $31.74 per share. These options, which expire on June 17, 2036, will vest on the first anniversary of the June 18, 2026 grant date, contingent on Hohneker's continued service. This Form 4 filing indicates a grant of derivative securities rather than an open-market purchase or sale of shares.
Arrivent Biopharma Inc stock hits 52-week high at 33.65 USD
Arrivent Biopharma Inc (AVBP) stock reached a 52-week high of $33.62, currently trading at $33.14. Despite this achievement, InvestingPro analysis suggests the stock is overvalued. The company recently filed for a $250 million at-the-market equity offering, and Cantor Fitzgerald reiterated an Overweight rating, favoring its firmonertinib for non-small cell lung cancer treatment.
Form 4 Arrivent Biopharma Inc For: 22 June By Investing.com
This article from Investing.com reports on a Form 4 filing for Arrivent Biopharma Inc pertaining to June 22. It mentions the stock symbol AVBP and its percentage change. The article itself is very brief and acts more as an announcement of the filing rather than an analysis.
Form 4 Arrivent Biopharma Inc For: 22 June By Investing.com
This article from Investing.com reports the filing of a Form 4 for Arrivent Biopharma Inc. on June 22. It is a very brief announcement, indicating a financial disclosure for the company.
ArriVent BioPharma (AVBP) director receives grant of 13,562 stock options
ArriVent BioPharma director Kristine Peterson was granted 13,562 non-qualified stock options at an exercise price of $31.74 per share. These options will vest on the first anniversary of the grant date, provided she continues her service, and are set to expire on June 17, 2036. This transaction is considered a neutral event, as it represents compensation rather than a direct purchase or sale of shares.
ArriVent BioPharma (AVBP) director receives 13,562 stock options grant
ArriVent BioPharma (AVBP) director Parsey Merdad was granted 13,562 non-qualified stock options at an exercise price of $31.74 per share, expiring on June 17, 2036. The options vest on the first anniversary of the June 18, 2026, grant date, contingent on Merdad's continued service. This award represents his total derivative securities after the transaction.
ArriVent BioPharma (NASDAQ: AVBP) 2026 meeting backs board, auditor
ArriVent BioPharma, Inc. announced the results of its 2026 annual meeting, where stockholders re-elected three Class II directors—James Healy, John Hohneker, and Stuart Lutzker—to serve until the 2029 annual meeting. Stockholders also ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. A quorum of 72.07% of eligible shares was present or represented by proxy, ensuring the validity of the meeting's decisions.
Arrivent Biopharma Inc stock hits 52-week high at 33.65 USD
Arrivent Biopharma Inc (NASDAQ:AVBP) stock reached a 52-week high of $33.62, currently trading at $33.14. This milestone follows the company's recent filing of a prospectus supplement for a $250 million at-the-market equity offering program and Cantor Fitzgerald reiterating an Overweight rating with a $27.00 price target. The positive market sentiment is driven by strong momentum and the potential of ArriVent’s firmonertinib for first-line treatment of non-small cell lung cancer.
Truist Financial Initiates ArriVent BioPharma(AVBP.US) With Buy Rating, Announces Target Price $31.74
Truist Financial has initiated coverage on ArriVent BioPharma (AVBP.US) with a Buy rating. The financial firm has also set a target price of $31.74 for the company's stock. This initiation suggests a positive outlook from Truist Financial on ArriVent BioPharma's future performance.
Arrivent Biopharma Inc stock hits 52-week high at 33.65 USD
Arrivent Biopharma Inc (AVBP) has reached a new 52-week high of $33.62, currently trading at $33.14. Despite this achievement, InvestingPro analysis suggests the stock is overvalued. The company has also filed for a $250 million at-the-market equity offering and received an Overweight rating from Cantor Fitzgerald, which favors its firmonertinib for lung cancer treatment.
ArriVent BioPharma (Nasdaq:AVBP) - Stock Analysis
ArriVent BioPharma (AVBP) is a clinical-stage biopharmaceutical company focused on developing cancer treatments. The company's stock is currently trading significantly below its estimated fair value, with analysts projecting a 37.5% price increase and strong revenue growth. Recent updates include analyst support, a $250 million equity offering, and IND clearance for a new drug ARR-002 targeting ovarian and endometrial cancers, alongside ongoing trials for firmonertinib in non-small cell lung cancer.
(AVBP) Price Dynamics and Execution-Aware Positioning
This article provides an AI-driven analysis of Arrivent Biopharma Inc. (NASDAQ: AVBP), indicating a near-term neutral sentiment amidst mid and long-term strength. It highlights a lack of resistance above the current price, suggesting upside potential. The analysis also details three distinct trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored to different risk profiles.
Arrivent Biopharma Inc (AVBP) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Arrivent Biopharma Inc (AVBP), detailing analyst ratings, target prices, and future EPS and revenue growth estimates. Based on 13 analysts, the company currently holds a "Buy" rating with a target price of 43.917 USD, representing a potential upside of 44.94%. The report also includes recent EPS performance and expectations for upcoming quarters.
Arrivent Biopharma Inc (AVBP) Financial Health: Profitability & Balance Sheet Analysis
This article provides a financial health analysis of Arrivent Biopharma Inc (AVBP) through TradingKey. It covers key financial metrics like cash and cash equivalents, total assets, liabilities, free cash flow, and operational efficiency. However, the analysis notes that relevant data for profitability, operational efficiency, growth potential, and shareholder returns have not yet been disclosed by the company.
Arrivent Biopharma Inc (AVBP) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis for Arrivent Biopharma Inc (AVBP), focusing on key metrics like P/E, P/B, P/S, and P/CF ratios. However, it notes that relevant data for these valuation metrics have not yet been disclosed by the company. The article presents the company's current stock price, market capitalization, and a general overview of its financial health and risk assessment factors.
Arrivent Biopharma Inc (AVBP) Risk Assessment: Volatility, Financial Risk & Investment Risk
This article provides a risk assessment for Arrivent Biopharma Inc (AVBP), detailing its volatility, financial risk, and investment risk metrics. It includes data such as Beta vs S&P 500 index, Maximum Drawdown, 240-Day Volatility, and various return and liquidity indicators. The analysis aims to help investors make informed decisions by presenting a comprehensive overview of the stock's risk profile.
AVBP: Directors were elected through 2029 and the auditor's appointment was ratified with strong support
ArriVent BioPharma, Inc. (AVBP) held its AGM 2026 virtually, electing three directors to serve until 2029 and ratifying PricewaterhouseCoopers LLP as the auditor for 2026. The meeting confirmed a quorum, and no questions were posed by stockholders during the Q&A session. This information is based on an AI-generated summary of the AGM audio transcript.
Arrivent Biopharma Inc (AVBP) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article from TradingKey focuses on Arrivent Biopharma Inc (AVBP) and attempts to provide a revenue breakdown by business segments and regional contributions. However, it explicitly states that the relevant data for both business and regional revenue have not been disclosed by the company yet. The article primarily provides market data for AVBP, including its current stock price, market cap, and a general company overview.
ArriVent BioPharma (AVBP) Stock Valuation After Growing Expectations For EGFR Firmonertinib Trials
ArriVent BioPharma (AVBP) is gaining investor attention due to growing expectations for its EGFR firmonertinib trials in non-small cell lung cancer. The stock, currently trading at US$30.30, shows steady returns but is still loss-making with a market cap of US$1.4 billion. While its Price-to-Book ratio suggests it's fairly valued compared to its direct peers, a discounted cash flow analysis indicates it might be significantly undervalued.
(AVBP) as a Liquidity Pulse for Institutional Tactics
This article analyzes Arrivent Biopharma Inc. (NASDAQ: AVBP), highlighting strong sentiment across all time horizons and an overweight bias based on AI models. It details three institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis and resistance/support levels for the stock. The report emphasizes the use of predictive AI for optimizing trading and risk management.
Analysts Offer Insights on Healthcare Companies: Vanda (VNDA), ArriVent BioPharma, Inc. (AVBP) and Medtronic (MDT)
Three analysts have issued bullish sentiments on healthcare companies Vanda (VNDA), ArriVent BioPharma, Inc. (AVBP), and Medtronic (MDT). H.C. Wainwright reiterated a Buy rating on Vanda with a $21.00 price target, while Citi analysts maintained Buy ratings on ArriVent BioPharma and Medtronic, setting price targets of $43.00 and $110.00 respectively. These reports suggest significant potential upside for all three stocks based on current analyst consensus.
AVBP Financials: Revenue Breakdown, Margins & Competitor Comparison
This article analyzes the financial health of ArriVent BioPharma Inc (AVBP), focusing on its profitability, margins, and market capitalization. It highlights the company's gross margin, operating margin, net margin, and Return on Equity (ROE), noting several metrics as N/A. The article also provides a competitive comparison against industry leaders CRON and BRBR, benchmarking AVBP's financial performance.
AVBP - ArriVent BioPharma Inc Stock Price and Quote
This article provides comprehensive stock information for ArriVent BioPharma Inc (AVBP), including its latest stock price, financial metrics, analyst ratings, and recent news. It details key financial figures, analyst price targets, and a timeline of significant company announcements, such as financial results, clinical trial updates, and corporate appointments. The data indicates investor and analyst interest in the biopharmaceutical company's growth and pipeline.
Guggenheim Remains a Buy on ArriVent BioPharma, Inc. (AVBP)
Guggenheim analyst Michael Schmidt reiterated a Buy rating on ArriVent BioPharma, Inc. (AVBP) and maintained a $45.00 price target. Schmidt, known for a 29.2% average return in the Healthcare sector, based his analysis partly on the company's Q1 GAAP net loss of $43.32 million, an improvement from $64.39 million last year. The broader analyst consensus for ArriVent BioPharma is a Strong Buy with an average price target of $44.56.
Cantor Fitzgerald reiterates Overweight on ArriVent BioPharma stock By Investing.com
Cantor Fitzgerald has reiterated its Overweight rating on ArriVent BioPharma (NASDAQ:AVBP) shares, highlighting the efficacy of its drug firmonertinib for non-small cell lung cancer, despite the stock's significant year-to-date surge. The firm's analysis, supported by key opinion leaders, suggests a strong preference for an oral tyrosine kinase inhibitor like firmonertinib over existing treatments due to better tolerability and patient experience. ArriVent recently announced a $250 million equity offering program and has received a "Buy" rating from BTIG with a target of $42.00, underscoring ongoing positive sentiment.
ArriVent BioPharma Price Target Raised to $45.00/Share From $43.00 by Truist Securities
Truist Securities has increased its price target for ArriVent BioPharma (AVBP) to $45.00 per share, up from $43.00. This adjustment by the financial firm indicates a positive outlook on the biopharmaceutical company's financial prospects and stock valuation.
Truist Financial Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Raises Target Price to $45
Truist Financial has reiterated its Buy rating on ArriVent BioPharma (AVBP.US) and increased its price target to $45. This adjustment reflects continued confidence in the biotechnology company.
LifeSci Capital Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Maintains Target Price $42
LifeSci Capital has reiterated its Buy rating on ArriVent BioPharma (AVBP.US) and maintained its price target of $42. This sustained bullish outlook suggests confidence in the company's future performance.
ArriVent BioPharma, Inc. (AVBP) Receives a Buy from Oppenheimer
Oppenheimer analyst Jeff Jones has reiterated a Buy rating on ArriVent BioPharma, Inc. (AVBP) and set a price target of $50.00. Jones, a 5-star analyst, covers the Healthcare sector with a strong track record. The analyst consensus for ArriVent BioPharma, Inc. is a Strong Buy with an average price target of $44.56, despite the company reporting a quarterly GAAP net loss of $35.54 million in its latest earnings release.
ArriVent (Nasdaq: AVBP) Q1 2026 loss narrows while pivotal cancer trials progress
ArriVent BioPharma (Nasdaq: AVBP) reported a narrower net loss of $43.3 million for Q1 2026, down from $64.4 million in Q1 2025, primarily due to reduced research and development expenses. The company is advancing pivotal Phase 3 trials for firmonertinib in non-small cell lung cancer and progressing its antibody-drug conjugate programs, ARR-002 and ARR-217. ArriVent projects its current cash and investments of $326.4 million will fund operations into Q4 2027.
ArriVent Reaffirmed at Buy as Lead Asset Nears 2026 Phase 3 Readout; $42 Price Target Maintained
LifeSci Capital analyst Sam Slutsky has reiterated a Buy rating for ArriVent BioPharma, Inc., maintaining a $42 price target. This affirmation is based on the upcoming mid-2026 Phase 3 data readout for firmonertinib in NSCLC, its FDA Breakthrough Therapy Designation, and positive results from a competitor's trial validating the therapeutic approach. The company's cash runway and early-stage ADC pipeline also contribute to the positive outlook.
ArriVent BioPharma (AVBP) files $250M ATM program with Jefferies
ArriVent BioPharma (AVBP) has filed a prospectus supplement announcing an "at the market" (ATM) program to offer up to $250 million of its common stock through Jefferies LLC as a sales agent. The company plans to use the net proceeds to support the development of its lead product candidate, firmonertinib, other pipeline programs, and for general corporate purposes. This offering is expected to result in an illustrative dilution of $19.38 per share for new investors, based on a $29.50 per share price and 45,308,941 shares outstanding as of March 31, 2026.
ArriVent BioPharma Releases Q1 2026 Financial Results
ArriVent BioPharma Inc. reported a narrower net loss for the first quarter of 2026, with a loss of $0.96 per share and a net loss of $43.3 million. This represents a 49.5% improvement year-over-year from Q1 2025's $1.90 per share loss. The company, which focuses on oncology therapeutics, maintains strong analyst confidence despite being in a pre-revenue stage.
Press Release: ArriVent BioPharma Reports First Quarter 2026 Financial Results
This article reports on ArriVent BioPharma's first-quarter 2026 financial results. It briefly mentions that Unity Software also reported its fourth-quarter earnings, with revenue increasing by 35% year-over-year to $609 million, exceeding estimates, while reporting a quarterly loss of 66 cents per share. The full details for ArriVent BioPharma require a login or account creation.
ArriVent BioPharma Updates At-The-Market Equity Offering Program
ArriVent BioPharma has updated its at-the-market equity offering program, allowing it to sell up to $250 million in common stock through Jefferies LLC. This move provides the company with flexible access to capital, potentially strengthening its balance sheet and funding pipeline activities, though it may also lead to dilution for existing shareholders. Currently, analysts rate AVBP as a Buy with a $44.00 price target, while TipRanks' AI Analyst, Spark, assigns a Neutral score due to mixed financial fundamentals despite positive technicals.
Arrivent BioPharma files prospectus supplement for $250 million at-the-market offering
ArriVent BioPharma (NASDAQ:AVBP) has filed a prospectus supplement for an at-the-market (ATM) equity offering program, aiming to raise up to $250 million through the sale of common stock via Jefferies LLC. The company's shares are currently trading at $29.02, reflecting a 47% year-to-date gain, and analysts note the company's strong cash position despite appearing overvalued. This move follows recent positive coverage from BTIG, which initiated a "buy" rating with a $42.00 price target, citing the potential of ArriVent's oncology drug, firmonertinib.
ArriVent BioPharma (NASDAQ: AVBP) adds $250M ATM stock flexibility
ArriVent BioPharma announced an increase in its "at-the-market" (ATM) stock offering program, allowing it to sell up to $250 million in common stock. This is facilitated through Jefferies LLC as the sales agent, under an Open Market Sale Agreement and an existing automatic shelf registration statement on Form S-3ASR. The expanded program provides ArriVent with flexibility to raise capital over time as needed.
ArriVent BioPharma (NASDAQ: AVBP) posts Q1 2026 loss and details oncology pipeline progress
ArriVent BioPharma reported a narrower net loss of $43.3 million in Q1 2026, compared to $64.4 million in the prior year, primarily due to reduced early-stage R&D spending. The company maintained a strong cash position of $326.4 million, sufficient to fund operations for at least 12 months, and made pipeline advancements, including ongoing Phase 3 trials for firmonertinib in NSCLC and a Phase 1 trial for ARR-217. They also raised $54.7 million through an at-the-market equity program and retain access to a $75 million term loan facility.
ArriVent BioPharma Inc reports results for the quarter ended March 31 - Earnings Summary
ArriVent BioPharma Inc. has reported its earnings for the quarter that ended on March 31. The summary provides an overview of the company's financial performance during this period. The report is published by Reuters and Refinitiv.
A Look At ArriVent BioPharma (AVBP) Valuation After FDA IND Clearance For ARR-002
ArriVent BioPharma received FDA clearance for its investigational new drug, ARR-002, a dual-target antibody-drug conjugate for ovarian and endometrial cancers. Despite recent short-term dips, the company has seen strong year-to-date and 1-year returns. The article analyzes ArriVent's valuation using Price-to-Book ratio and Discounted Cash Flow models, suggesting it may be trading at a discount despite appearing expensive relative to the broader biotech industry.
Press Release: ArriVent BioPharma Reports First Quarter 2026 Financial Results
ArriVent BioPharma announced its first-quarter 2026 financial results, providing an update on its financial performance and operational highlights for the period. This press release outlines the company's fiscal standing and any significant developments during the first three months of 2026.
